{"id":41808,"date":"2025-09-18T15:42:23","date_gmt":"2025-09-18T07:42:23","guid":{"rendered":"https:\/\/flcube.com\/?p=41808"},"modified":"2025-09-18T15:42:23","modified_gmt":"2025-09-18T07:42:23","slug":"eli-lillys-orforglipron-outperforms-oral-semaglutide-in-achieve%e2%80%913-phase-3-trial","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=41808","title":{"rendered":"Eli Lilly\u2019s Orforglipron Outperforms Oral Semaglutide in ACHIEVE\u20113 Phase\u202f3 Trial"},"content":{"rendered":"\n<p><strong>Eli Lilly and Company (<a href=\"https:\/\/www.google.com\/finance\/quote\/LLY:NYSE\">NYSE: LLY<\/a>)<\/strong> announced <strong>positive topline results<\/strong> from the open\u2011label, randomized <strong>Phase\u202f3 ACHIEVE\u20113<\/strong> study. The trial evaluated <strong>orforglipron<\/strong>, an oral GLP\u20111 receptor agonist, against <strong>oral semaglutide<\/strong> in <strong>1,698 adults<\/strong> with type\u202f2 diabetes inadequately controlled with metformin.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-study-design\">Study Design<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Open\u2011label, head\u2011to\u2011head<\/strong> comparing <strong>orforglipron 12\u202fmg &amp; 36\u202fmg<\/strong> vs. <strong>oral semaglutide 7\u202fmg &amp; 14\u202fmg<\/strong>.<\/li>\n\n\n\n<li>52\u2011week duration, <strong>approved\u2011label dosing<\/strong> for semaglutide and <strong>once\u2011daily dosing<\/strong> for orforglipron, <strong>no food or water restrictions<\/strong>.<\/li>\n\n\n\n<li>Primary endpoint: <strong>A1C reduction<\/strong>; secondary endpoints: <strong>A1C &lt;\u202f5.7\u202f%<\/strong>, <strong>weight loss<\/strong>, and cardiovascular risk markers.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-key-results\">Key Results<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Outcome<\/th><th>Orforglipron 12\u202fmg<\/th><th>Orforglipron 36\u202fmg<\/th><th>Oral Semaglutide 7\u202fmg<\/th><th>Oral Semaglutide 14\u202fmg<\/th><\/tr><\/thead><tbody><tr><td>Mean A1C \u2193<\/td><td>1.9\u202f%<\/td><td>2.2\u202f%<\/td><td>1.1\u202f%<\/td><td>1.4\u202f%<\/td><\/tr><tr><td>% achieving A1C\u202f&lt;\u202f5.7\u202f%<\/td><td>\u2013<\/td><td><strong>37.1\u202f%<\/strong><\/td><td>\u2013<\/td><td><strong>12.5\u202f%<\/strong><\/td><\/tr><tr><td>Mean weight loss<\/td><td>14.6\u202flb (6.7\u202f%)<\/td><td>19.7\u202flb (9.2\u202f%)<\/td><td>7.9\u202flb (3.7\u202f%)<\/td><td>11.0\u202flb (5.3\u202f%)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Orforglipron<\/strong> met <strong>all primary and key secondary endpoints<\/strong> and delivered <strong>73.6\u202f% greater relative weight loss<\/strong> at the highest dose.<\/li>\n\n\n\n<li>Significant improvements were also seen in <strong>non\u2011HDL cholesterol, systolic BP, and triglycerides<\/strong>.<\/li>\n\n\n\n<li>The safety profile remained consistent with earlier trials, with no new safety signals.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-implications-for-diabetes-therapy\">Implications for Diabetes Therapy<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Orforglipron<\/strong> offers a <strong>once\u2011daily, food\u2011independent regimen<\/strong> that may enhance patient adherence.<\/li>\n\n\n\n<li>The superior glycemic and weight\u2011loss benefits position it as a compelling next\u2011step for patients failing metformin.<\/li>\n\n\n\n<li>Eli\u202fLilly\u2019s portfolio expansion into non\u2011peptide GLP\u20111 agonists underscores its commitment to innovative diabetes solutions.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/li>\n<\/ul>\n","protected":false},"excerpt":{"rendered":"<p>Eli Lilly and Company (NYSE: LLY) announced positive topline results from the open\u2011label, randomized Phase\u202f3&#8230;<\/p>\n","protected":false},"author":1,"featured_media":41809,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[17,39,199,4361,911],"class_list":["post-41808","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-clinical-trial-results","tag-diabetes","tag-eli-lilly","tag-hot-targets","tag-nyse-lly"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Eli Lilly\u2019s Orforglipron Outperforms Oral Semaglutide in ACHIEVE\u20113 Phase\u202f3 Trial - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Eli Lilly and Company (NYSE: LLY) announced positive topline results from the open\u2011label, randomized Phase\u202f3 ACHIEVE\u20113 study. The trial evaluated orforglipron, an oral GLP\u20111 receptor agonist, against oral semaglutide in 1,698 adults with type\u202f2 diabetes inadequately controlled with metformin.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=41808\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Eli Lilly\u2019s Orforglipron Outperforms Oral Semaglutide in ACHIEVE\u20113 Phase\u202f3 Trial\" \/>\n<meta property=\"og:description\" content=\"Eli Lilly and Company (NYSE: LLY) announced positive topline results from the open\u2011label, randomized Phase\u202f3 ACHIEVE\u20113 study. The trial evaluated orforglipron, an oral GLP\u20111 receptor agonist, against oral semaglutide in 1,698 adults with type\u202f2 diabetes inadequately controlled with metformin.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=41808\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-09-18T07:42:23+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/1809.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=41808#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=41808\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Eli Lilly\u2019s Orforglipron Outperforms Oral Semaglutide in ACHIEVE\u20113 Phase\u202f3 Trial\",\"datePublished\":\"2025-09-18T07:42:23+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=41808\"},\"wordCount\":229,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=41808#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/1809.webp\",\"keywords\":[\"Clinical trial results\",\"Diabetes\",\"Eli Lilly\",\"Hot targets\",\"NYSE: LLY\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=41808#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=41808\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=41808\",\"name\":\"Eli Lilly\u2019s Orforglipron Outperforms Oral Semaglutide in ACHIEVE\u20113 Phase\u202f3 Trial - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=41808#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=41808#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/1809.webp\",\"datePublished\":\"2025-09-18T07:42:23+00:00\",\"description\":\"Eli Lilly and Company (NYSE: LLY) announced positive topline results from the open\u2011label, randomized Phase\u202f3 ACHIEVE\u20113 study. The trial evaluated orforglipron, an oral GLP\u20111 receptor agonist, against oral semaglutide in 1,698 adults with type\u202f2 diabetes inadequately controlled with metformin.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=41808#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=41808\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=41808#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/1809.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/1809.webp\",\"width\":1080,\"height\":608,\"caption\":\"Eli\u202fLilly\u2019s Orforglipron Outperforms Oral Semaglutide in ACHIEVE\u20113 Phase\u202f3 Trial\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=41808#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Eli Lilly\u2019s Orforglipron Outperforms Oral Semaglutide in ACHIEVE\u20113 Phase\u202f3 Trial\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Eli Lilly\u2019s Orforglipron Outperforms Oral Semaglutide in ACHIEVE\u20113 Phase\u202f3 Trial - Insight, China&#039;s Pharmaceutical Industry","description":"Eli Lilly and Company (NYSE: LLY) announced positive topline results from the open\u2011label, randomized Phase\u202f3 ACHIEVE\u20113 study. The trial evaluated orforglipron, an oral GLP\u20111 receptor agonist, against oral semaglutide in 1,698 adults with type\u202f2 diabetes inadequately controlled with metformin.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=41808","og_locale":"en_US","og_type":"article","og_title":"Eli Lilly\u2019s Orforglipron Outperforms Oral Semaglutide in ACHIEVE\u20113 Phase\u202f3 Trial","og_description":"Eli Lilly and Company (NYSE: LLY) announced positive topline results from the open\u2011label, randomized Phase\u202f3 ACHIEVE\u20113 study. The trial evaluated orforglipron, an oral GLP\u20111 receptor agonist, against oral semaglutide in 1,698 adults with type\u202f2 diabetes inadequately controlled with metformin.","og_url":"https:\/\/flcube.com\/?p=41808","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-09-18T07:42:23+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/1809.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=41808#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=41808"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Eli Lilly\u2019s Orforglipron Outperforms Oral Semaglutide in ACHIEVE\u20113 Phase\u202f3 Trial","datePublished":"2025-09-18T07:42:23+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=41808"},"wordCount":229,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=41808#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/1809.webp","keywords":["Clinical trial results","Diabetes","Eli Lilly","Hot targets","NYSE: LLY"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=41808#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=41808","url":"https:\/\/flcube.com\/?p=41808","name":"Eli Lilly\u2019s Orforglipron Outperforms Oral Semaglutide in ACHIEVE\u20113 Phase\u202f3 Trial - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=41808#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=41808#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/1809.webp","datePublished":"2025-09-18T07:42:23+00:00","description":"Eli Lilly and Company (NYSE: LLY) announced positive topline results from the open\u2011label, randomized Phase\u202f3 ACHIEVE\u20113 study. The trial evaluated orforglipron, an oral GLP\u20111 receptor agonist, against oral semaglutide in 1,698 adults with type\u202f2 diabetes inadequately controlled with metformin.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=41808#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=41808"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=41808#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/1809.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/1809.webp","width":1080,"height":608,"caption":"Eli\u202fLilly\u2019s Orforglipron Outperforms Oral Semaglutide in ACHIEVE\u20113 Phase\u202f3 Trial"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=41808#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Eli Lilly\u2019s Orforglipron Outperforms Oral Semaglutide in ACHIEVE\u20113 Phase\u202f3 Trial"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/1809.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/41808","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=41808"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/41808\/revisions"}],"predecessor-version":[{"id":41810,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/41808\/revisions\/41810"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/41809"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=41808"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=41808"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=41808"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}